Vidaza (azacitidine) Disease Interactions
There are 4 disease interactions with Vidaza (azacitidine):
Azacitidine (applies to Vidaza) hepatic tumors
Major Potential Hazard, Moderate plausibility.
The use of azacitidine injection is contraindicated in patients with advanced malignant hepatic tumors.
Azacitidine (applies to Vidaza) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Azacitidine is potentially hepatotoxic in patients with preexisting hepatic impairment and caution should be exercised when prescribing in patients with liver disease.
Azacitidine (applies to Vidaza) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Patients with renal impairment may be at increased risk of renal toxicity when using azacitidine. This drug is primarily excreted by the kidneys. Therefore, these patients should be closely monitored for toxicity.
Miscellaneous antineoplastics (applies to Vidaza) anemia
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neutropenia, Thrombocytopenia
Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.
Vidaza (azacitidine) drug interactions
There are 124 drug interactions with Vidaza (azacitidine)
More about Vidaza (azacitidine)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- 13 Reviews
- Generic Availability
- Drug class: miscellaneous antineoplastics
- FDA Approval History
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|